Inclusion Criteria

Inclusion criteria

- Patients with histological or cytological confirmed advanced solid tumors, which
progressed despite standard therapy or for whom no standard therapy exists

- Life expectancy of at least 3 months

- No dysfunction of bone marrow

- No major impairment of renal and hepatic function

Exclusion criteria

- Gastrointestinal dysfunction, such as gastrectomy or malabsorption syndrome, that
could alter absorption of the study drug

- Receipt of any investigational compound within the 28 days prior to the first dose of
study drug, or failure to recover from the side effects of such prior therapy

- Receipt of other antineoplastic therapy including chemotherapy, hormone therapy,
immunotherapy, radiation therapy within the 28 days

- Patients known to be HIV, or hepatitis B or C viruses positive, or patients with the
presence of active or suspected acute or chronic uncontrolled infection

- Patients with a history of allergies to the camptothecin family of drugs

Other protocol-defined inclusion/exclusion criteria may apply